Sun, 04 Dec 2022

NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

CNTA Shareholders Click Here: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=33988&wire=1
OPEN Shareholders Click Here: https://www.zlk.com/pslra-1/opendoor-technologies-loss-submission-form?prid=33988&wire=1
OLPX Shareholders Click Here: https://www.zlk.com/pslra-1/olaplex-holdings-lawsuit-submission-form?prid=33988&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, November 23, 2022, Press release picture

Centessa Pharmaceuticals plc (NASDAQ:CNTA)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022.
Lead Plaintiff Deadline : November 28, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=33988&wire=1

According to the filed complaint, (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Opendoor Technologies Incorporated (NASDAQ:OPEN)

This lawsuit is on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired: (a) Opendoor securities between December 21, 2020 and September 16, 2022, both dates inclusive and/or (b) Opendoor common stock pursuant and/or traceable to documents issued in connection with the business combination between the Company and Opendoor Labs Inc. completed on or about December 18, 2020.
Lead Plaintiff Deadline : December 6, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/opendoor-technologies-loss-submission-form?prid=33988&wire=1

According to the filed complaint, (i) the algorithm used by the Company to make offers for homes could not accurately adjust to changing house prices across different market conditions and economic cycles; (ii) as a result, the Company was at an increased risk of sustaining significant and repeated losses due to residential real estate pricing fluctuations; (iii) accordingly, defendants overstated the purported benefits and competitive advantages of the algorithm; (iv) as a result, documents issued in connection with the merger between the Company and Opendoor Labs Inc. and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Olaplex Holdings, Inc. (NASDAQ:OLPX)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Olaplex common stock pursuant and/or traceable to the Company's initial public offering conducted on or around September 30, 2021.
Lead Plaintiff Deadline : January 17, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/olaplex-holdings-lawsuit-submission-form?prid=33988&wire=1

According to the filed complaint, (i) macroeconomic pressures and competition in the haircare market were more robust than the Company had represented to investors; (ii) accordingly, the Company was unlikely to maintain its sales and revenue momentum; and (iii) as a result, it was unlikely that the Company would be able to achieve the financial and operational growth projected in the offering documents; and (iv) as a result, the offering documents were materially false and/or misleading and failed to state information required to be stated therein.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/728054/CLASS-ACTION-UPDATE-for-CNTA-OPEN-and-OLPX-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Sign up for Buffalo News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!